-
Product Insights
He Dreiht
He Dreiht is an offshore wind project located in North Sea, Germany. The project is owned and being developed by EnBW He Dreiht GmbH. The project is at the permitting stage. Empower your strategies with our He Dreiht report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report...
-
Product Insights
Sanliurfa HES
Sanliurfa HES is a Hydro project located in Sanliurfa, Turkey. The project is owned by Devlet su Isleri Genel Mudurlugu. The project came online in 2005. Empower your strategies with our Sanliurfa HES report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered...
-
Product Insights
Dogancay HES
Dogancay HES is a Hydro project located in Adana, Turkey. The project is owned by Enerjisa Enerji Uretim AS. The project came online in 2017. Empower your strategies with our Dogancay HES report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based...
-
Product Insights
NewLikelihood of Approval Analysis for Hypereosinophilic Syndrome
Overview How likely is it that the drugs in Hypereosinophilic Syndrome will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hypereosinophilic Syndrome Overview Hypereosinophilic syndrome (HES) is a disease characterized by a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Benralizumab in Skin Rash
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Benralizumab in Skin Rash report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Benralizumab in Skin Rash Drug Details: Benralizumab (Fasenra) is a glyco-engineered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMS-001 in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMS-001 in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMS-001 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMS-001 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMS-001 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMS-001 in Secondary Progressive Multiple Sclerosis (SPMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMS-001 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMS-001 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMS-001 in Primary Progressive Multiple Sclerosis (PPMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Benralizumab in Churg-Strauss Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Benralizumab in Churg-Strauss Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Benralizumab in Churg-Strauss Syndrome Drug Details: Benralizumab (Fasenra) is a glyco-engineered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Benralizumab in Prurigo
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Benralizumab in Prurigo Drug Details: Benralizumab (Fasenra) is a glyco-engineered monoclonal antibody, acts as an...